Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Elizabeth A. Schackmann"'
Autor:
Kirsten Timms, James M. Ford, Shaveta Vinayak, Anosheh Afghahi, Melinda L. Telli, Robert W. Carlson, Anne-Renee Hartman, Kristin C. Jensen, Elizabeth A. Schackmann, Pei-Jen Chang, Allison W. Kurian
Publikováno v:
Clinical Cancer Research. 23:3365-3370
Purpose: In germline BRCA1 or BRCA2 (BRCA1/2) mutation carriers, restoration of tumor BRCA1/2 function by a secondary mutation is recognized as a mechanism of resistance to platinum and PARP inhibitors, primarily in ovarian cancer. We evaluated this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92ab26a2623ef2e7332254033abddcfa
https://doi.org/10.1158/1078-0432.ccr-16-2174
https://doi.org/10.1158/1078-0432.ccr-16-2174
Autor:
Joseph A. Sparano, Shaker R. Dakhil, Pei-Jen Chang, Bobbie Head, Victor Abkevich, Kirsten Timms, Julia Reid, Irene Wapnir, Judith Manola, Barbara Haley, Elizabeth A. Schackmann, Anne Renee Hartman, James M. Ford, Robert W. Carlson, Allison W. Kurian, Patrick Flaherty, Shaveta Vinayak, Melinda L. Telli, Lori J. Goldstein, Jafi A. Lipson, Kristin C. Jensen
Publikováno v:
Journal of Clinical Oncology. 33:1895-1901
Purpose This study was designed to assess efficacy, safety, and predictors of response to iniparib in combination with gemcitabine and carboplatin in early-stage triple-negative and BRCA1/2 mutation–associated breast cancer. Patients and Methods Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::854b92836b3b991f60e5f4490c710051
https://doi.org/10.1200/jco.2014.57.0085
https://doi.org/10.1200/jco.2014.57.0085
Autor:
R. Lor Randall, Angelica R. Putnam, Elizabeth A. Schackmann, James F. Amatruda, Xiaomeng Huang, Heinrich Kovar, Christian N. Paxton, Jamie D. Gardiner, Joshua D. Schiffman, Lisa M. Abegglen, Marcus Stucki, Bryce E. Carter, Stephen L. Lessnick
Publikováno v:
Oncotarget
Oncotarget, vol 8, iss 16
Oncotarget, vol 8, iss 16
CEBPB copy number gain in Ewing sarcoma was previously shown to be associated with worse clinical outcome compared to tumors with normal CEBPB copy number, although the mechanism was not characterized. We employed gene knockdown and rescue assays to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6cc50a75839a0dd1372c9b284d012b36
https://pubmed.ncbi.nlm.nih.gov/28148901
https://pubmed.ncbi.nlm.nih.gov/28148901
Autor:
Sylvia K. Plevritis, Allison W. Kurian, Elizabeth A. Schackmann, Meredith A. Mills, Diego F. Munoz
Publikováno v:
Familial Cancer. 12:65-73
Women with BRCA1 or BRCA2 (BRCA1/2) mutations face difficult decisions about managing their high risks of breast and ovarian cancer. We developed an online tool to guide decisions about cancer risk reduction (available at: http://brcatool.stanford.ed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::20902b710304a3b4311ce833859da685
https://doi.org/10.1007/s10689-012-9577-8
https://doi.org/10.1007/s10689-012-9577-8
Autor:
Kerry Kingham, Ani Kardashian, Monique A. de Bruin, Debra M. Ikeda, Lisa A. McPherson, Elizabeth A. Schackmann, Bhavna Sharma, Ava Kwong, Allison W. Kurian, Jafi A. Lipson, James M. Ford, Meredith A. Mills, Benjamin A. Goldstein, Dee W. West
Publikováno v:
Familial Cancer. 11:429-439
The prevalence and penetrance of BRCA1 and BRCA2 (BRCA1/2) mutations may differ between Asians and whites. We investigated BRCA1/2 mutations and cancer risk factors in a clinic-based sample. BRCA1/2 mutation carriers were enrolled from cancer genetic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4de9f190299a02ff1eaddfde943af1c5
https://doi.org/10.1007/s10689-012-9531-9
https://doi.org/10.1007/s10689-012-9531-9
Autor:
Sylvia K. Plevritis, Diego F. Munoz, Lauren Clarke, Elizabeth A. Schackmann, Peter Rust, Meredith A. Mills, Maxwell L. Smith, Allison W. Kurian
Publikováno v:
Journal of Clinical Oncology. 30:497-506
Purpose Women with BRCA1 or BRCA2 (BRCA1/2) mutations must choose between prophylactic surgeries and screening to manage their high risks of breast and ovarian cancer, comparing options in terms of cancer incidence, survival, and quality of life. A c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::257080c0c6a55e748a3f63d95d0c9694
https://doi.org/10.1200/jco.2011.38.6060
https://doi.org/10.1200/jco.2011.38.6060
Autor:
Elizabeth A. Schackmann, Ava Kwong, Ani Kardashian, B Sharma, Allison W. Kurian, Kerry Kingham, Jafi A. Lipson, Bruin Ma de, Meredith A. Mills, Debra M. Ikeda, Dee W. West, Lisa A. McPherson, James M. Ford, Benjamin A. Goldstein
Publikováno v:
Cancer Research. 71:P4-10
Background Prior research suggests that the prevalence and penetrance of BRCA1/2 mutations may be different in Asians compared with Caucasians. Such differences in penetrance could be related to genetic, as well as hormonal, reproductive and lifestyl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1c1368f4922dfc2cd6eda16a8ae15a84
https://doi.org/10.1158/0008-5472.sabcs11-p4-10-10
https://doi.org/10.1158/0008-5472.sabcs11-p4-10-10
Autor:
Kirstin C. Jensen, Allison W. Kurian, Elizabeth A. Schackmann, Meredith A. Mills, Robert W. Carlson, James M. Ford, C. Rocha, Shaveta Vinayak, Barry M. Sherman, Melinda L. Telli, Bruce L. Daniel, A Blackwood-Chirchir, Charles Bradley, Patrick Flaherty, P-J Chang, Irene Wapnir, Jafi A. Lipson
Publikováno v:
Cancer Research. 71:P3-14
Background The combination of gemcitabine, platinum and inhibition of DNA repair results in synergistic chemosensitivity in triple-negative and BRCA1-deficient breast cancer cell lines. This study was designed to assess efficacy, safety and predictor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fbe1ce6436d1f22350cdb66962d75ba9
https://doi.org/10.1158/0008-5472.sabcs11-p3-14-08
https://doi.org/10.1158/0008-5472.sabcs11-p3-14-08
Autor:
Erich J. Schwartz, Elizabeth A. Schackmann, Adrian M. Fernandez, Elizabeth Alli, Allison W. Kurian, Ani Kardashian, Meredith A. Mills, Ashley D. Staton, James M. Ford, Vandana B. Sharma, Shaveta Vinayak, Melinda L. Telli, Lisa A. McPherson, Jafi A. Lipson, Kristin C. Jensen
Pre-clinical and epidemiologic studies provide rationale for evaluating lipophilic statins for breast cancer prevention. We conducted a single-arm, biomarker modulation trial of lovastatin among women with increased risk of breast cancer. Eligibility
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9917ed5bc5dec49b3bb243bd31122546
https://europepmc.org/articles/PMC5508753/
https://europepmc.org/articles/PMC5508753/
Autor:
Angelica R. Putnam, Jamie D. Gardiner, R. Lor Randall, Marcus Stucki, Bryce E. Carter, Elizabeth A. Schackmann, Clinton C. Mason, Stephen L. Lessnick, Heinrich Kovar, Joshua D. Schiffman, Lisa M. Abegglen
Publikováno v:
Cancer Research. 75:483-483
We previously identified increased copies of CEBPB in a subset of Ewing sarcoma (ES) tumors, and this gain was associated with worse clinical outcome. Due to CEBPB's role in cell growth and differentiation, as well as the gene's ability to transform
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::965ea715310366ab209b4e35f1c388b6
https://doi.org/10.1158/1538-7445.am2015-483
https://doi.org/10.1158/1538-7445.am2015-483